Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL).

Matthew S. Davids(Dana-Farber Cancer Institute), William G. Wierda(University of Maryland, Baltimore), Lori A. Gressick(AbbVie (United States)), Andrew W. Roberts(The Royal Melbourne Hospital), Thomas J. Kipps(University of California San Diego), John M. Pagel(University of Washington), Brenda Chyla(AbbVie (United States)), Brad S. Kahl(UW Health University Hospital), John F. Gerecitano(Memorial Sloan Kettering Cancer Center), John F. Seymour(The Royal Melbourne Hospital), Ming Zhu(AbbVie (United States)), Su Young Kim(Yonsei University), Soham D. Puvvada(University of Arizona), Maria E. Verdugo(AbbVie (United States)), Martin Dunbar(AbbVie (United States))
Journal of Clinical Oncology
May 20, 2016
10.1200/jco.2016.34.15_suppl.7527
Cited by 13

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k